Home > Insider Trading > Filing (0000899243-22-001525)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658551	Amylyx Pharmaceuticals Inc.	AMLX	Pharmaceutical Preparations (2834)	464600503

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1829696	Isaac Cheng	C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-06	1,409,035	$0.00	1,409,035	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2022-01-06	6,410,964	$0.00	7,819,999	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2022-01-06	974,107	$0.00	8,794,106	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2022-01-06	1,621,544	$0.00	10,415,650	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2022-01-06	6,578	$19.00	6,578	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2022-01-06	1,409,035	$0.00	1,409,035	$0.00
Common Stock	Series B Preferred Stock	Disposition	2022-01-06	6,410,964	$0.00	6,410,964	$0.00
Common Stock	Series C-1 Preferred Stock	Disposition	2022-01-06	974,107	$0.00	974,107	$0.00
Common Stock	Series C-2 Preferred Stock	Disposition	2022-01-06	1,621,544	$0.00	1,621,544	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-01-06	8,400	$0.00	8,400	$19.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
8,400	2032-01-06	No	4	A	Direct

Footnotes

Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.